-
Mashup Score: 47Towards AI-assisted cardiology: a reflection on the performance and limitations of using large language models in clinical decision-making - 12 month(s) ago
The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)
Source: eurointervention.pcronline.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 126
The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)
Source: eurointervention.pcronline.comCategories: General Medicine News, CardiologistsTweet-
In the OPERA-TAVI registry, matched patients undergoing TAVI using Evolut PRO/PRO+ and Sapien 3 ULTRA devices exhibited comparable rates of the composite endpoint of all-cause mortality, rehospitalisation for heart failure, or disabling stroke at 1 year. https://t.co/BlZWQ6FGPN https://t.co/2O5bEYKEku
-
-
Mashup Score: 127Evaluating the pharmacokinetic and pharmacodynamic impact of different modes of ticagrelor administration - 1 year(s) ago
Alternative administration modes for oral P2Y12 inhibitors, particularly ticagrelor, have emerged as a potential alternative to overcome the limitations associated with the delayed onset of action …
Source: www.tandfonline.comCategories: General Medicine News, CardiologistsTweet-
Alternative administration modes for ticagrelor (i.e., crushed, chewed, or orodispersible tablets) are an alternative to overcome the limitations associated with its delayed onset of action in patients who are unable to swallow or with impaired absorption. https://t.co/sgDyfJX0M6 https://t.co/UzCaTUbnw4
-
-
Mashup Score: 155Prognostic impact of cardiac damage staging classification in each aortic stenosis subtype undergoing TAVI - 1 year(s) ago
The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)
Source: eurointervention.pcronline.comCategories: General Medicine News, CardiologistsTweet-
In this prospective TAVI registry of 2,090 patients across the hemodynamic spectrum of severe aortic stenosis, the cardiac damage staging classification stratified the risk of death irrespective of aortic stenosis subtypes (e.g., high or low gradient). https://t.co/THeg0k7BGd https://t.co/9m7xjOS2KT
-
-
Mashup Score: 154Prognostic impact of cardiac damage staging classification in each aortic stenosis subtype undergoing TAVI - 1 year(s) ago
The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)
Source: eurointervention.pcronline.comCategories: General Medicine News, CardiologistsTweet-
In this prospective TAVI registry of 2,090 patients across the hemodynamic spectrum of severe aortic stenosis, the cardiac damage staging classification stratified the risk of death irrespective of aortic stenosis subtypes (e.g., high or low gradient). https://t.co/THeg0k7BGd https://t.co/9m7xjOS2KT
-
-
Mashup Score: 33Stopping Aspirin Within 1 Month After Stenting for Ticagrelor Monotherapy in Acute Coronary Syndrome: The T-PASS Randomized Noninferiority Trial - 1 year(s) ago
Background: Stopping aspirin within 1 month after implantation of a drug-eluting stent (DES) for ticagrelor monotherapy has not been exclusively evaluated for patients with acute coronary syndrome (A
Source: www.ahajournals.orgCategories: General Medicine News, CardiologistsTweet-
In T-PASS, aspirin discontinuation after a median of 16 days, followed by ticagrelor monotherapy, was superior for NACE compared with 12-mo DAPT in 2850 patients with ACS, with less bleeding. But KM curves opened late, which is a bit puzzling. #TCT2023 https://t.co/GAEGEpykmL
-
-
Mashup Score: 154Prognostic impact of cardiac damage staging classification in each aortic stenosis subtype undergoing TAVI - 1 year(s) ago
The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)
Source: eurointervention.pcronline.comCategories: General Medicine News, CardiologistsTweet-
In this prospective TAVI registry of 2,090 patients across the hemodynamic spectrum of severe aortic stenosis, the cardiac damage staging classification stratified the risk of death irrespective of aortic stenosis subtypes (e.g., high or low gradient). https://t.co/THeg0k7BGd https://t.co/9m7xjOS2KT
-
-
Mashup Score: 38Association of trial characteristics with simultaneous publication and its impact on citations and mentions: a cross-sectional study - 1 year(s) ago
Randomized trials are often presented at medical conferences and published simultaneously or later. Predictors of simultaneous publication and its con…
Source: www.sciencedirect.comCategories: General Medicine News, CardiologistsTweet-
In this study, we investigated the phenomenon of simultaneous publication of cardiovascular trials and found some predictors. Simultaneous publications were associated with higher citation and mention metrics compared with nonsimultaneous publications. https://t.co/LDw7poHYJQ https://t.co/Byhxe7IVpW
-
-
Mashup Score: 161Navigating the Course of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: A Review of Guided Approaches - 1 year(s) ago
Dual antiplatelet therapy (DAPT) is the standard approach to prevent thrombotic events in patients undergoing percutaneous coronary intervention and presenting with chronic or acute coronary syndrome
Source: www.ahajournals.orgCategories: General Medicine News, CardiologistsTweet-
The goal of guided DAPT is to intensify or decrease the antiplatelet potency based on risk. We wrote this article to present an up-to-date overview of the latest research findings on DAPT modulation guided by either platelet function or genetic testing. https://t.co/99jcmBr9rA https://t.co/SzuUtDnjej
-
-
Mashup Score: 300Late-Breaking Science announced - 1 year(s) ago
See the impressive lineup of Late-Breaking Science on tap for presentation in Philadelphia.
Source: sessions.hub.heart.orgCategories: General Medicine News, CardiologistsTweet-
Trials of this year's #AHA that intrigue me the most: 1) SELECT on semaglutide 2) ORBITA-2 on PCI 3) DAPA-MI on dapagliflozin 4) AZALEA on abelacimab 5) ARTESIA on apixaban 6) REMAIN-2 on recaticimab 7) A trial of lepodisiran 8) VERVE-101 on gene editing https://t.co/cP74P3GsyW
-
In this article, discussing the performance and limitations of using AI in clinical decision-making, the authors designed two clinical vignettes that were presented to #ChatGPT, and found significantly different responses based on query presentation... https://t.co/O5ztVr22gH https://t.co/l6njP8XOhw